Differential pharmacology and clinical utility of emerging combination treatments in the management of COPD - Role of umeclidinium/vilanterol

International Journal of COPD

Volumn 9, Issue , 2014, Pages 687-695

  Malerba, Mario ^a   Morjaria, Jaymin Bhagwanji ^b   Radaeli, Alessandro ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF HULL   (United Kingdom)

^c Department of Emergency Spedali Civili di Brescia ^*  (Italy)

Author keywords

Bronchodilators combination; COPD treatment; Long acting beta2 agonists; Long acting muscarinic receptor antagonists; Umeclidinium; Vilanterol

Indexed keywords

FORMOTEROL; INDACATEROL; MOXIFLOXACIN; MUSCARINIC M3 RECEPTOR; PLACEBO; RESPIMAT; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; UNCLASSIFIED DRUG; VERAPAMIL; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

AIRWAY OBSTRUCTION; ANXIETY DISORDER; BLURRED VISION; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLOSED ANGLE GLAUCOMA; CONSTIPATION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG POTENTIATION; DRUG TOLERABILITY; DYSPEPSIA; FORCED EXPIRATORY VOLUME; GASTROESOPHAGEAL REFLUX; GLAUCOMA; GLYCOGENOLYSIS; HEADACHE; HEALTH STATUS; HEART ARRHYTHMIA; HEART PALPITATION; HEART RATE VARIABILITY; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; KIDNEY DISEASE; LIVER DISEASE; LUNG FUNCTION; MONOTHERAPY; NERVOUSNESS; PAPILLEDEMA; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POWDER INHALER; QUALITY OF LIFE; REVIEW; RHINOPHARYNGITIS; SINGLE DRUG DOSE; SUPRAVENTRICULAR TACHYCARDIA; TREMOR; URINARY TRACT DISEASE; URINE RETENTION; XEROSTOMIA; CONVALESCENCE; DRUG COMBINATION; DRUG EFFECTS; LUNG; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DRUG COMBINATIONS; HUMANS; LUNG; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; RECOVERY OF FUNCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84903585872     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S47792     Document Type: Review

References (50)

1. Qaseem A, Wilt TJ, Weinberger SE, et al; American College of Physicians; American College of Chest Physicians; American Thoracic Society; European Respiratory Society. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011;155(3):179-191.
2. Global Inititaive for Obstructive Lung Disease [homepage on the Internet]. Global strategy for the diagnosis, management and prevention of COPD; 2011 [updated Jan 2014]. Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.html. Accessed May 18, 2014.
3. Donohue JF, Ohar JA. Bronchodilator therapy of airway disease. In: Chung KF, Barnes PJ, editors. Pharmacology and Therapeutics of Airway Disease. New York: Informa Healthcare USA; 2009:198-225.
4. Ohar JA, Donohue JF. Mono and combination therapy of long-acting bronchodilators and inhaled corticosteroids in advanced COPD. Semin Respir Crit Care Med. 2010;31(3):321-333.
5. Gross NJ, Co E, Skorodin MS. Cholinergic bronchomotor tone in COPD. Estimates of its amount in comparison with that in normal subjects. Chest. 1989;96(5):984-987.
6. US Food and Drug Administration. FNA News Release. December18, 2013. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm379057.htm. Accessed May 18, 2014.
7. Salmon M, Luttmann MA, Foley JJ, et al. Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther. 2013;345(2):260-270.
8. Tal-Singer R, Cahn A, Mehta R, et al. Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: two randomised studies. Eur J Pharmacol. 2013;701(1-3):40-48.
9. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umecli-dinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol. 2013;185(2):393-399.
10. Trivedi R, Richard N, Mehta R, Church A. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J. 2014;43(1):72-81.
11. Malerba M, Radaeli A, Morjaria JB. Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects. Drug Discov Today. 2012;17(9-10): 496-504.
12. Barrett VJ, Emmons A, Ford AJ, Knowles R. In vitro pharmacological characterisation of GW642444, a novel long acting β2-agonist (LABA) using human recombinant β1/2/3 adrenoceptor cAMP assays [Abstract]. Am J Respir Crit Care Med. 2010;181:A4451.
13. Procopiou PA, Barrett VJ, Bevan NJ, et al. Synthesis and structure-activity relationships of long-acting beta2 adrenergic receptor agonists incorporating metabolic inactivation: an antedrug approach. J Med Chem. 2010;53(11):4522-4530.
14. Ford AJ, Hughes S, Smith C, Somers G, Ranshaw L. The therapeutic index of vilanterol trifenatate [Abstract]. Eur Respir J. 2010;24:208s.
15. Kempsford R, Norris V, Siederer S. GW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in asth-matic patients [Abstract]. Am J Respir Crit Care Med. 2010;181:A5413.
16. Kempsford R, Norris V, Siederer S. GW642444, a novel inhaled long-acting β2 adrenoceptor agonist (LABA), at single doses of 25, 50 and 100 mcg, is well tolerated and demonstrates prolonged bronchodilation in COPD patients [Abstract]. Am J Respir Crit Care Med. 2010;181:A4447.
17. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, iswell tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm Pharmacol Ther. 2013;26(2):256-264.
18. Hanania NA, Feldman G, Zachgo W, et al. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest. 2012;142(1):119-127.
19. Kesten S, Celli B, Decramer M, Leimer I, Tashkin D. Tiotropium HandiHaler in the treatment of COPD: a safety review. Int J Chron Obstruct Pulmon Dis. 2009;4:397-409.
20. Kizer KM, Bess DT, Bedford NK. Blurred vision from ipratropium bromide inhalation. Am J Health Syst Pharm. 1999;56(9):914.
21. Mulpeter KM, Walsh JB, O'Connor M, O'Connell F, Burke C. Ocular hazards of nebulized bronchodilators. Postgrad Med J. 1992;68(796): 132-133.
22. Pras E, Stienlauf S, Pinkhas J, Sidi Y. Urinary retention associated with ipratropium bromide. DICP. 1991;25(9):939-940.
23. Stephenson A, Seitz D, Bell CM, et al. Inhaled anticholinergic drug therapy and the risk of acute urinary retention in chronic obstructive pulmonary disease: a population-based study. Arch Intern Med. 2011;171(10):914-920.
24. Mann JS, Howarth PH, Holgate ST. Bronchoconstriction induced by ipratropium bromide in asthma: relation to hypotonicity. Br Med J (Clin Res Ed). 1984;289(6443):469.
25. Lee TA, Pickard AS, Au DH, Bartle B, Weiss KB. Risk for death associated with medications for recently diagnosed chronic obstructive pulmonary disease. Ann Intern Med. 2008;149(6):380-390.
26. Tashkin DP, Celli B, Senn S, et al; UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359(15):1543-1554.
27. Singh S, Loke YK, Enright PL, Furberg CD. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. BMJ. 2011;342:d3215.
28. Wise RA, Anzueto A, Calverley P, et al. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale. Respir Res. 2013;14:40.
29. Wise RA, Anzueto A, Cotton D, et al; TIOSPIR Investigators. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med. 2013;369(16):1491-1501.
30. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res. 2010;11:149.
31. Knudson RJ, Constantine HP. An effect of isoproterenol on ventilation-perfusion in asthmatic versus normal subjects. J Appl Physiol. 1967;22(3):402-406.
32. Wagner PD, Dantzker DR, Iacovoni VE, Tomlin WC, West JB. Ventilation-perfusion inequality in asymptomatic asthma. Am Rev Respir Dis. 1978;118(3):511-524.
33. Philipson LH. Beta-agonists and metabolism. J Allergy Clin Immunol. 2002;110(Suppl 6):S313-S317.
34. Tesfamariam B, Waldron T, Seymour AA. Quantitation of tremor in response to beta-adrenergic receptor stimulation in primates: relationship with hypokalemia. J Pharmacol Toxicol Methods. 1998;40(4): 201-205.
35. Kelleher DL, Mehta RS, Jean-Francois BM, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of umeclidinium and vilanterol alone and in combination: a randomized crossover trial. PLoS One. 2012;7(12):e50716.
36. Kelleher D, Tombs L, Crater G, Preece A, Brealey N, Mehta R. A placebo and moxifloxacin-controlled thorough QT study of umeclidinium monotherapy and umeclidinium/vilanterol combination in healthy subjects [Abstract]. Am J Respir Crit Care Med. 2013;187: A1487.
37. Mehta R, Kelleher D, Preece A, Hughes S, Crater G. Effect of verapamil on systemic exposure and safety of umeclidinium and vilanterol: a randomized and open-label study. Int J Chron Obstruct Pulmon Dis. 2013;8:159-167.
38. Mehta R, Hardes K, Kelleher D, Preece A, Tombs L, Brealey N. Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [Abstract]. Eur Respir J. 2013;42:Suppl 57; A3641.
39. Kelleher D, Hardes K, Brealey N, Tombs L, Preece A, Mehta R. Effect of severe renal impairment (SRI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK) [Abstract]. Eur Respir J. 2013;42:Suppl 57; P4148.
40. Feldman G, Walker RR, Brooks J, Mehta R, Crater G. 28-Day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther. 2012;25(6):465-471.
41. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25mcg in COPD. Respir Med. 2013;107(10):1538-1546.
42. Celli BR, Crater G, Kilbride S, et al. A 24-week randomized, double-blind, placebo-controlled study of the efficacy and safety of once-daily umeclidinium/vilanterol 125/25 mcg in COPD [Abstract]. Am J Respir Crit Care Med. 2013;187:A2435.
43. Decramer M, Anzueto A, Kerwin E, et al. Efficacy and safety of umecli-dinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472-486.
44. clinicaltrials.gov [homepage on the Internet]. DB2113374: a multicenter trial comparing the efficacy and safety of GSK573719/GW642444 with GSK573719 and with tiotropium over 24 weeks in subjects with chronic obstructive pulmonary disease (COPD). ClinicalTrials.gov identifier NCT01316913; 2011 [updated January 9, 2014]. Available from: http://clinicaltrials.gov/show/NCT01316913. Accessed May 18, 2014.
45. clinicaltrials.gov [homepage on the Internet]. A 52 week, multi-centre, open-label study to evaluate the safety and tolerability of GSK573719/GW642444 125 mcg once-daily in combination with GW642444
46. mcg once-daily via novel dry powder inhaler (nDPI) in Japanese subjects with chronic obstructive pulmonary disease. ClinicalTrials.gov identifier NCT01376388; 2011 [updated February 13, 2014]. Available from: http://clinicaltrials.gov/show/NCT01376388. Accessed May 18, 2014.
47. FDA Advisory Committee Briefing Document. ANORO™ ELLIPTA™ (Umeclidinium Bromide/Vilanterol Inhalation Powder) For Treatment of Chronic Obstructive Pulmonary Disease. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Pulmonary-AllergyDrugsAdvisoryCommittee/UCM367414.pdf. Accessed May 28, 2014.
48. Prakash A, Babu KS, Morjaria JB. Novel anti-cholinergics in COPD. Drug Discov Today. 2013;18(21-22):1117-1126.
49. Cazzola M, Segreti A, Matera MG. New developments in the combination treatment of COPD: focus on umeclidinium/vilanterol. Drug Des Devel Ther. 2013;7:1201-1208.
50. Feldman GJ, Edin A. The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: current evidence and future prospects. Ther Adv Respir Dis. 2013;7(6):311-319.